Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 34 | 2021 | 765 | 6.590 |
Why?
|
Brain Neoplasms | 38 | 2020 | 638 | 6.240 |
Why?
|
Neoplasm Metastasis | 21 | 2021 | 220 | 3.830 |
Why?
|
Neoplastic Stem Cells | 13 | 2019 | 99 | 3.700 |
Why?
|
MicroRNAs | 11 | 2021 | 180 | 3.240 |
Why?
|
Gene Expression Regulation, Neoplastic | 26 | 2021 | 261 | 3.010 |
Why?
|
Prostatic Neoplasms | 14 | 2016 | 471 | 2.780 |
Why?
|
Bone Neoplasms | 7 | 2021 | 111 | 2.600 |
Why?
|
Neoplasms | 15 | 2020 | 728 | 2.260 |
Why?
|
Radiosurgery | 19 | 2020 | 356 | 2.180 |
Why?
|
Cell Line, Tumor | 35 | 2021 | 726 | 2.110 |
Why?
|
Signal Transduction | 16 | 2020 | 682 | 1.930 |
Why?
|
Mice | 34 | 2021 | 2484 | 1.930 |
Why?
|
Genes, Tumor Suppressor | 7 | 2015 | 34 | 1.880 |
Why?
|
Microglia | 3 | 2020 | 57 | 1.870 |
Why?
|
Animals | 49 | 2021 | 7542 | 1.860 |
Why?
|
Lung Neoplasms | 10 | 2021 | 414 | 1.840 |
Why?
|
Mice, Nude | 16 | 2021 | 291 | 1.570 |
Why?
|
Exosomes | 3 | 2021 | 43 | 1.460 |
Why?
|
Humans | 95 | 2021 | 32114 | 1.420 |
Why?
|
Cell Proliferation | 14 | 2019 | 604 | 1.340 |
Why?
|
Apoptosis | 10 | 2018 | 360 | 1.280 |
Why?
|
Nicotine | 2 | 2021 | 174 | 1.240 |
Why?
|
Macrophages | 3 | 2017 | 191 | 1.230 |
Why?
|
Antineoplastic Agents | 8 | 2018 | 608 | 1.180 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2018 | 19 | 1.170 |
Why?
|
Neoplasm Proteins | 4 | 2020 | 148 | 1.160 |
Why?
|
Neoplasm Invasiveness | 11 | 2016 | 190 | 1.110 |
Why?
|
Female | 55 | 2021 | 20015 | 1.110 |
Why?
|
Cell Cycle Proteins | 6 | 2018 | 55 | 1.050 |
Why?
|
Kangai-1 Protein | 4 | 2011 | 4 | 1.020 |
Why?
|
Promoter Regions, Genetic | 7 | 2019 | 208 | 1.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 5 | 2015 | 70 | 0.990 |
Why?
|
Neovascularization, Pathologic | 5 | 2017 | 82 | 0.850 |
Why?
|
Magnetic Field Therapy | 2 | 2019 | 17 | 0.830 |
Why?
|
rho GTP-Binding Proteins | 2 | 2015 | 10 | 0.820 |
Why?
|
Calcium Channels, T-Type | 2 | 2019 | 29 | 0.820 |
Why?
|
Disease Progression | 10 | 2019 | 594 | 0.810 |
Why?
|
Wnt Proteins | 3 | 2012 | 18 | 0.800 |
Why?
|
Calcium | 3 | 2019 | 307 | 0.750 |
Why?
|
Receptors, Cell Surface | 4 | 2015 | 70 | 0.740 |
Why?
|
Neutrophils | 1 | 2021 | 106 | 0.710 |
Why?
|
Immunity, Innate | 1 | 2020 | 75 | 0.700 |
Why?
|
Gene Expression Profiling | 7 | 2019 | 322 | 0.690 |
Why?
|
Activating Transcription Factor 3 | 2 | 2011 | 6 | 0.670 |
Why?
|
Connexins | 1 | 2019 | 3 | 0.660 |
Why?
|
Inhibitor of Differentiation Protein 2 | 1 | 2019 | 5 | 0.660 |
Why?
|
Lung | 1 | 2021 | 249 | 0.650 |
Why?
|
Duffy Blood-Group System | 3 | 2007 | 4 | 0.640 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2019 | 367 | 0.640 |
Why?
|
Microfilament Proteins | 1 | 2018 | 31 | 0.620 |
Why?
|
Up-Regulation | 9 | 2018 | 189 | 0.620 |
Why?
|
Male | 35 | 2020 | 19217 | 0.590 |
Why?
|
Tumor Suppressor Proteins | 3 | 2008 | 71 | 0.560 |
Why?
|
Osteonectin | 1 | 2016 | 17 | 0.550 |
Why?
|
Bone Morphogenetic Protein 7 | 2 | 2016 | 18 | 0.540 |
Why?
|
RNA, Untranslated | 1 | 2016 | 10 | 0.530 |
Why?
|
Disease Models, Animal | 6 | 2019 | 1022 | 0.530 |
Why?
|
Models, Biological | 6 | 2019 | 392 | 0.520 |
Why?
|
GTP-Binding Proteins | 2 | 2006 | 23 | 0.520 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2015 | 210 | 0.520 |
Why?
|
Stilbenes | 2 | 2016 | 23 | 0.510 |
Why?
|
Phosphoric Monoester Hydrolases | 2 | 2005 | 11 | 0.510 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2015 | 7 | 0.500 |
Why?
|
Neoplasm Transplantation | 7 | 2018 | 73 | 0.500 |
Why?
|
Cyclooxygenase 2 | 1 | 2015 | 48 | 0.490 |
Why?
|
beta Catenin | 2 | 2012 | 37 | 0.490 |
Why?
|
NF-kappa B | 2 | 2014 | 81 | 0.490 |
Why?
|
Astrocytes | 2 | 2019 | 58 | 0.470 |
Why?
|
Kruppel-Like Transcription Factors | 2 | 2014 | 16 | 0.470 |
Why?
|
Cranial Irradiation | 6 | 2020 | 93 | 0.450 |
Why?
|
Salvage Therapy | 6 | 2020 | 134 | 0.450 |
Why?
|
Survival Analysis | 10 | 2020 | 483 | 0.450 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2016 | 82 | 0.440 |
Why?
|
Xenograft Model Antitumor Assays | 8 | 2019 | 115 | 0.440 |
Why?
|
Receptors, Notch | 1 | 2013 | 16 | 0.440 |
Why?
|
Transplantation, Heterologous | 5 | 2018 | 122 | 0.430 |
Why?
|
Prognosis | 11 | 2020 | 1497 | 0.430 |
Why?
|
Genes, Neoplasm | 2 | 2010 | 18 | 0.420 |
Why?
|
Drug Design | 2 | 2012 | 43 | 0.420 |
Why?
|
Fatty Acid Synthesis Inhibitors | 1 | 2012 | 3 | 0.420 |
Why?
|
Patents as Topic | 1 | 2012 | 2 | 0.420 |
Why?
|
Epithelial Cells | 2 | 2010 | 141 | 0.410 |
Why?
|
Endothelial Cells | 3 | 2010 | 189 | 0.410 |
Why?
|
Transfection | 7 | 2015 | 191 | 0.400 |
Why?
|
Rats | 7 | 2013 | 1596 | 0.400 |
Why?
|
Intracellular Signaling Peptides and Proteins | 5 | 2012 | 73 | 0.400 |
Why?
|
Mice, SCID | 6 | 2013 | 71 | 0.400 |
Why?
|
Glucuronosyltransferase | 1 | 2011 | 5 | 0.400 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 6 | 2015 | 263 | 0.390 |
Why?
|
Stromal Cells | 1 | 2011 | 84 | 0.380 |
Why?
|
Sterol Regulatory Element Binding Proteins | 1 | 2010 | 1 | 0.370 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2010 | 37 | 0.370 |
Why?
|
Sesquiterpenes | 1 | 2010 | 5 | 0.370 |
Why?
|
Middle Aged | 24 | 2020 | 11839 | 0.370 |
Why?
|
Electromagnetic Fields | 3 | 2020 | 26 | 0.370 |
Why?
|
Glioblastoma | 3 | 2018 | 156 | 0.360 |
Why?
|
Metabolic Networks and Pathways | 1 | 2010 | 19 | 0.350 |
Why?
|
Mammary Glands, Human | 1 | 2010 | 15 | 0.350 |
Why?
|
Blotting, Western | 7 | 2015 | 289 | 0.340 |
Why?
|
STAT3 Transcription Factor | 2 | 2021 | 25 | 0.340 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2010 | 57 | 0.340 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2020 | 60 | 0.340 |
Why?
|
Fibroblasts | 1 | 2010 | 111 | 0.330 |
Why?
|
Membrane Glycoproteins | 2 | 2006 | 101 | 0.330 |
Why?
|
Treatment Outcome | 12 | 2019 | 3306 | 0.320 |
Why?
|
Focal Adhesion Kinase 2 | 1 | 2008 | 2 | 0.320 |
Why?
|
Retrospective Studies | 15 | 2020 | 3510 | 0.320 |
Why?
|
Sterol Regulatory Element Binding Protein 1 | 1 | 2008 | 6 | 0.310 |
Why?
|
Liver Neoplasms | 2 | 2020 | 155 | 0.310 |
Why?
|
Aged | 18 | 2020 | 10314 | 0.300 |
Why?
|
Transcription Factors | 3 | 2019 | 181 | 0.300 |
Why?
|
Enzyme Activation | 4 | 2020 | 135 | 0.290 |
Why?
|
RNA Interference | 4 | 2013 | 76 | 0.280 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 101 | 0.280 |
Why?
|
Membrane Proteins | 4 | 2018 | 256 | 0.270 |
Why?
|
Vitamin E | 1 | 2006 | 23 | 0.270 |
Why?
|
Cell Communication | 2 | 2017 | 32 | 0.260 |
Why?
|
Cell Adhesion | 3 | 2016 | 108 | 0.260 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 3 | 2010 | 6 | 0.260 |
Why?
|
Endothelium, Vascular | 1 | 2006 | 156 | 0.250 |
Why?
|
Brain | 3 | 2018 | 951 | 0.250 |
Why?
|
Immunohistochemistry | 4 | 2019 | 538 | 0.250 |
Why?
|
Cell Movement | 5 | 2018 | 169 | 0.250 |
Why?
|
Apoptosis Regulatory Proteins | 3 | 2010 | 40 | 0.250 |
Why?
|
Smoking | 2 | 2021 | 528 | 0.250 |
Why?
|
Blood-Brain Barrier | 2 | 2015 | 48 | 0.240 |
Why?
|
Mice, Knockout | 2 | 2021 | 443 | 0.240 |
Why?
|
Reactive Oxygen Species | 4 | 2015 | 157 | 0.240 |
Why?
|
Mesenchymal Stem Cells | 2 | 2017 | 182 | 0.240 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 2 | 2016 | 36 | 0.240 |
Why?
|
Melanoma | 4 | 2019 | 164 | 0.230 |
Why?
|
Mammary Neoplasms, Experimental | 2 | 2015 | 29 | 0.230 |
Why?
|
Postural Balance | 1 | 2016 | 182 | 0.230 |
Why?
|
Mice, Inbred BALB C | 2 | 2020 | 167 | 0.220 |
Why?
|
Pesticides | 1 | 2016 | 199 | 0.220 |
Why?
|
Aged, 80 and over | 9 | 2019 | 3990 | 0.220 |
Why?
|
Occupational Exposure | 1 | 2016 | 232 | 0.220 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 244 | 0.210 |
Why?
|
Transients and Migrants | 1 | 2016 | 297 | 0.210 |
Why?
|
Transcription, Genetic | 3 | 2016 | 137 | 0.210 |
Why?
|
Cytokines | 2 | 2017 | 256 | 0.210 |
Why?
|
Solidago | 1 | 2002 | 1 | 0.200 |
Why?
|
Phytotherapy | 1 | 2002 | 38 | 0.200 |
Why?
|
Osteoclasts | 1 | 2021 | 22 | 0.200 |
Why?
|
Plant Extracts | 1 | 2002 | 61 | 0.190 |
Why?
|
Cells, Cultured | 2 | 2015 | 834 | 0.190 |
Why?
|
Receptors, Estrogen | 1 | 2021 | 113 | 0.190 |
Why?
|
Receptor, erbB-2 | 2 | 2019 | 65 | 0.190 |
Why?
|
Gene Knockdown Techniques | 4 | 2019 | 77 | 0.190 |
Why?
|
Neutrophil Infiltration | 1 | 2021 | 13 | 0.190 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2015 | 160 | 0.190 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2013 | 105 | 0.180 |
Why?
|
Chemokine CCL20 | 1 | 2020 | 6 | 0.180 |
Why?
|
Citric Acid Cycle | 1 | 2020 | 11 | 0.180 |
Why?
|
Protein Transport | 2 | 2017 | 74 | 0.180 |
Why?
|
Pyruvate Dehydrogenase Complex | 1 | 2020 | 18 | 0.180 |
Why?
|
Receptors, Immunologic | 1 | 2020 | 21 | 0.180 |
Why?
|
Antigens, Differentiation | 1 | 2020 | 25 | 0.180 |
Why?
|
Cell Survival | 4 | 2020 | 285 | 0.180 |
Why?
|
DNA Methylation | 2 | 2016 | 141 | 0.180 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2020 | 37 | 0.180 |
Why?
|
Lipogenesis | 2 | 2010 | 18 | 0.180 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2020 | 84 | 0.170 |
Why?
|
Tumor Cells, Cultured | 3 | 2006 | 171 | 0.170 |
Why?
|
Syndecan-1 | 1 | 2019 | 11 | 0.170 |
Why?
|
Plasma Cells | 1 | 2019 | 11 | 0.170 |
Why?
|
HMGA2 Protein | 1 | 2019 | 13 | 0.170 |
Why?
|
Hispanic Americans | 1 | 2016 | 940 | 0.170 |
Why?
|
Cyclophosphamide | 2 | 2010 | 38 | 0.170 |
Why?
|
Adult | 10 | 2020 | 9380 | 0.170 |
Why?
|
Tissue Array Analysis | 1 | 2019 | 34 | 0.170 |
Why?
|
Chalcone | 1 | 2019 | 3 | 0.170 |
Why?
|
Cystatin A | 1 | 2019 | 8 | 0.170 |
Why?
|
Interleukin-23 Subunit p19 | 1 | 2019 | 11 | 0.160 |
Why?
|
MAP Kinase Signaling System | 1 | 2019 | 61 | 0.160 |
Why?
|
Porifera | 1 | 2018 | 2 | 0.160 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2019 | 21 | 0.160 |
Why?
|
Myeloid Cells | 1 | 2019 | 39 | 0.160 |
Why?
|
Antigens, Neoplasm | 1 | 2019 | 45 | 0.160 |
Why?
|
Carcinoma, Bronchogenic | 1 | 2018 | 7 | 0.160 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2018 | 21 | 0.160 |
Why?
|
Tyrosine | 1 | 2018 | 23 | 0.160 |
Why?
|
RNA, Neoplasm | 1 | 2018 | 20 | 0.160 |
Why?
|
Disulfides | 1 | 2018 | 36 | 0.160 |
Why?
|
Computational Biology | 2 | 2016 | 91 | 0.160 |
Why?
|
Biopsy, Fine-Needle | 1 | 2018 | 53 | 0.160 |
Why?
|
Costs and Cost Analysis | 1 | 2018 | 100 | 0.160 |
Why?
|
Acidosis | 2 | 2015 | 18 | 0.160 |
Why?
|
Proto-Oncogene Proteins | 2 | 2010 | 85 | 0.160 |
Why?
|
Survival Rate | 4 | 2020 | 877 | 0.150 |
Why?
|
Down-Regulation | 1 | 2018 | 142 | 0.150 |
Why?
|
Adenocarcinoma | 2 | 2019 | 308 | 0.150 |
Why?
|
Neoplasm Staging | 1 | 2019 | 447 | 0.150 |
Why?
|
Cell Separation | 1 | 2017 | 92 | 0.140 |
Why?
|
Nervous System Neoplasms | 1 | 2017 | 8 | 0.140 |
Why?
|
Medicare | 1 | 2018 | 206 | 0.140 |
Why?
|
Mitochondria | 2 | 2016 | 187 | 0.140 |
Why?
|
TNF Receptor-Associated Factor 6 | 1 | 2016 | 4 | 0.140 |
Why?
|
Caspase 3 | 2 | 2010 | 33 | 0.140 |
Why?
|
Meningeal Neoplasms | 1 | 2017 | 49 | 0.140 |
Why?
|
Base Sequence | 4 | 2016 | 252 | 0.140 |
Why?
|
bcl-X Protein | 1 | 2016 | 5 | 0.140 |
Why?
|
Azacitidine | 1 | 2016 | 28 | 0.140 |
Why?
|
Alternative Splicing | 1 | 2016 | 30 | 0.140 |
Why?
|
DNA, Neoplasm | 1 | 2016 | 55 | 0.140 |
Why?
|
Colonic Neoplasms | 1 | 2016 | 71 | 0.130 |
Why?
|
Systems Biology | 1 | 2016 | 10 | 0.130 |
Why?
|
Follow-Up Studies | 5 | 2020 | 2265 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2015 | 3 | 0.130 |
Why?
|
Nucleotides | 1 | 2015 | 16 | 0.130 |
Why?
|
RNA, Small Interfering | 3 | 2019 | 114 | 0.130 |
Why?
|
Receptors, CCR7 | 1 | 2015 | 3 | 0.130 |
Why?
|
PTEN Phosphohydrolase | 2 | 2005 | 21 | 0.130 |
Why?
|
Oncogene Protein v-akt | 1 | 2014 | 4 | 0.120 |
Why?
|
Epigenesis, Genetic | 1 | 2016 | 104 | 0.120 |
Why?
|
Sarcoma | 1 | 2016 | 73 | 0.120 |
Why?
|
Disease-Free Survival | 3 | 2017 | 317 | 0.120 |
Why?
|
Caspases | 2 | 2006 | 39 | 0.120 |
Why?
|
Neoplasm, Residual | 1 | 2014 | 25 | 0.120 |
Why?
|
Mice, Inbred NOD | 1 | 2013 | 25 | 0.110 |
Why?
|
NIH 3T3 Cells | 1 | 2013 | 43 | 0.110 |
Why?
|
Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2012 | 1 | 0.110 |
Why?
|
Calcium-Binding Proteins | 1 | 2013 | 45 | 0.110 |
Why?
|
Interleukin-1beta | 1 | 2013 | 42 | 0.110 |
Why?
|
Culture Media, Conditioned | 1 | 2013 | 51 | 0.110 |
Why?
|
Repressor Proteins | 1 | 2013 | 50 | 0.110 |
Why?
|
Stem Cell Niche | 1 | 2013 | 27 | 0.110 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 46 | 0.110 |
Why?
|
Inflammation | 1 | 2016 | 530 | 0.100 |
Why?
|
DNA Damage | 1 | 2012 | 99 | 0.100 |
Why?
|
Protein Isoforms | 2 | 2016 | 57 | 0.100 |
Why?
|
Genes, myc | 1 | 2012 | 5 | 0.100 |
Why?
|
Phosphorylation | 3 | 2020 | 229 | 0.100 |
Why?
|
Bone Morphogenetic Protein Receptors, Type II | 1 | 2011 | 3 | 0.100 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2011 | 9 | 0.100 |
Why?
|
Hymecromone | 1 | 2011 | 1 | 0.100 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2012 | 11 | 0.100 |
Why?
|
Chemokines | 1 | 2012 | 35 | 0.100 |
Why?
|
Time Factors | 2 | 2017 | 2151 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2011 | 7 | 0.100 |
Why?
|
Drug Delivery Systems | 2 | 2010 | 104 | 0.090 |
Why?
|
Ovarian Neoplasms | 1 | 2012 | 96 | 0.090 |
Why?
|
Luciferases, Renilla | 1 | 2010 | 2 | 0.090 |
Why?
|
Enzyme Inhibitors | 2 | 2009 | 166 | 0.090 |
Why?
|
Genes, Reporter | 1 | 2010 | 40 | 0.090 |
Why?
|
Drug Synergism | 1 | 2010 | 66 | 0.090 |
Why?
|
Tumor Burden | 1 | 2010 | 58 | 0.090 |
Why?
|
Molecular Sequence Data | 2 | 2012 | 359 | 0.090 |
Why?
|
Paclitaxel | 1 | 2010 | 67 | 0.090 |
Why?
|
Mesoderm | 1 | 2010 | 14 | 0.090 |
Why?
|
Receptor, Adenosine A3 | 1 | 2009 | 1 | 0.090 |
Why?
|
Acetyl-CoA Carboxylase | 1 | 2010 | 23 | 0.090 |
Why?
|
Aldehyde Reductase | 1 | 2009 | 3 | 0.090 |
Why?
|
Aldehydes | 1 | 2009 | 5 | 0.090 |
Why?
|
Malondialdehyde | 1 | 2009 | 11 | 0.090 |
Why?
|
Gene Expression | 1 | 2010 | 338 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2009 | 28 | 0.080 |
Why?
|
Focal Adhesion Kinase 1 | 1 | 2008 | 3 | 0.080 |
Why?
|
Cell Growth Processes | 1 | 2008 | 9 | 0.080 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2008 | 14 | 0.080 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2008 | 30 | 0.080 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2008 | 37 | 0.080 |
Why?
|
Carcinogens | 1 | 2008 | 35 | 0.080 |
Why?
|
Spheroids, Cellular | 2 | 2018 | 37 | 0.080 |
Why?
|
Hypoxia-Inducible Factor 1 | 1 | 2008 | 3 | 0.080 |
Why?
|
Lipids | 1 | 2009 | 232 | 0.080 |
Why?
|
Cell Hypoxia | 1 | 2008 | 41 | 0.080 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2008 | 80 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2008 | 104 | 0.070 |
Why?
|
Restriction Mapping | 1 | 2006 | 14 | 0.070 |
Why?
|
Plasmids | 1 | 2006 | 48 | 0.070 |
Why?
|
Mammary Glands, Animal | 1 | 2007 | 65 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 1 | 2007 | 85 | 0.070 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 9 | 0.070 |
Why?
|
Caspases, Initiator | 1 | 2006 | 1 | 0.070 |
Why?
|
Tocopherols | 1 | 2006 | 3 | 0.070 |
Why?
|
T-Box Domain Proteins | 1 | 2006 | 14 | 0.070 |
Why?
|
Flow Cytometry | 2 | 2009 | 185 | 0.070 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2006 | 23 | 0.070 |
Why?
|
Heterozygote | 1 | 2006 | 59 | 0.070 |
Why?
|
Protein Structure, Tertiary | 1 | 2006 | 99 | 0.070 |
Why?
|
Amino Acid Sequence | 1 | 2006 | 285 | 0.070 |
Why?
|
Alleles | 1 | 2006 | 248 | 0.070 |
Why?
|
Risk Factors | 3 | 2019 | 3880 | 0.060 |
Why?
|
Combined Modality Therapy | 2 | 2018 | 560 | 0.060 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 753 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 458 | 0.060 |
Why?
|
Proteins | 1 | 2005 | 144 | 0.060 |
Why?
|
Cell Cycle | 2 | 2015 | 77 | 0.060 |
Why?
|
Prospective Studies | 2 | 2019 | 2283 | 0.060 |
Why?
|
Case-Control Studies | 1 | 2016 | 898 | 0.060 |
Why?
|
Cohort Studies | 2 | 2018 | 1817 | 0.050 |
Why?
|
Cell Division | 1 | 2002 | 99 | 0.050 |
Why?
|
North Carolina | 1 | 2016 | 1538 | 0.050 |
Why?
|
Phosphoserine | 1 | 2020 | 8 | 0.050 |
Why?
|
Catalytic Domain | 1 | 2020 | 65 | 0.050 |
Why?
|
Stress, Physiological | 1 | 2020 | 55 | 0.050 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2019 | 20 | 0.040 |
Why?
|
SOXB1 Transcription Factors | 1 | 2019 | 18 | 0.040 |
Why?
|
Tissue Fixation | 1 | 2019 | 10 | 0.040 |
Why?
|
Paraffin Embedding | 1 | 2019 | 10 | 0.040 |
Why?
|
Formaldehyde | 1 | 2019 | 11 | 0.040 |
Why?
|
Risk | 1 | 2020 | 321 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2019 | 48 | 0.040 |
Why?
|
Radiometry | 1 | 2019 | 40 | 0.040 |
Why?
|
Organ Specificity | 1 | 2019 | 81 | 0.040 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 166 | 0.040 |
Why?
|
Histone Deacetylases | 1 | 2018 | 8 | 0.040 |
Why?
|
Culture Techniques | 1 | 2018 | 13 | 0.040 |
Why?
|
Recurrence | 1 | 2019 | 263 | 0.040 |
Why?
|
Drug Discovery | 1 | 2018 | 32 | 0.040 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2018 | 58 | 0.040 |
Why?
|
Postoperative Period | 1 | 2018 | 97 | 0.040 |
Why?
|
Monomeric GTP-Binding Proteins | 1 | 2018 | 6 | 0.040 |
Why?
|
Transcriptional Activation | 1 | 2018 | 42 | 0.040 |
Why?
|
Microtubule-Associated Proteins | 1 | 2018 | 35 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2018 | 294 | 0.040 |
Why?
|
RNA-Binding Proteins | 1 | 2018 | 68 | 0.040 |
Why?
|
Nomograms | 1 | 2017 | 32 | 0.040 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2019 | 154 | 0.040 |
Why?
|
Hearing Tests | 1 | 2017 | 13 | 0.040 |
Why?
|
Brain Death | 1 | 2017 | 26 | 0.040 |
Why?
|
bcl-2 Homologous Antagonist-Killer Protein | 1 | 2016 | 2 | 0.040 |
Why?
|
E1A-Associated p300 Protein | 1 | 2016 | 2 | 0.040 |
Why?
|
Cytosol | 1 | 2016 | 25 | 0.040 |
Why?
|
Lysine | 1 | 2016 | 23 | 0.040 |
Why?
|
Ubiquitination | 1 | 2016 | 16 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2017 | 149 | 0.030 |
Why?
|
RNA Precursors | 1 | 2016 | 2 | 0.030 |
Why?
|
Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2016 | 2 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2016 | 11 | 0.030 |
Why?
|
Retreatment | 1 | 2016 | 41 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2016 | 101 | 0.030 |
Why?
|
Sulfonamides | 1 | 2016 | 67 | 0.030 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2015 | 66 | 0.030 |
Why?
|
Incidence | 1 | 2019 | 1199 | 0.030 |
Why?
|
Protein Binding | 1 | 2016 | 201 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2016 | 108 | 0.030 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 35 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2017 | 464 | 0.030 |
Why?
|
Radiation Injuries | 1 | 2016 | 76 | 0.030 |
Why?
|
Deoxycytidine Kinase | 1 | 2015 | 2 | 0.030 |
Why?
|
Guanosine Triphosphate | 1 | 2015 | 8 | 0.030 |
Why?
|
Tumor Stem Cell Assay | 1 | 2015 | 12 | 0.030 |
Why?
|
Nucleosides | 1 | 2015 | 10 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2015 | 33 | 0.030 |
Why?
|
Carcinoma, Renal Cell | 1 | 2017 | 114 | 0.030 |
Why?
|
Databases, Factual | 1 | 2017 | 355 | 0.030 |
Why?
|
Immunotherapy | 1 | 2016 | 81 | 0.030 |
Why?
|
Osteosarcoma | 1 | 2015 | 11 | 0.030 |
Why?
|
Estrogens | 1 | 2016 | 180 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2014 | 65 | 0.030 |
Why?
|
Proteome | 1 | 2015 | 39 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2014 | 91 | 0.030 |
Why?
|
Models, Theoretical | 1 | 2016 | 137 | 0.030 |
Why?
|
Homeodomain Proteins | 1 | 2014 | 51 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2016 | 508 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 2017 | 201 | 0.030 |
Why?
|
Lipid Metabolism | 1 | 2015 | 105 | 0.030 |
Why?
|
HCT116 Cells | 1 | 2012 | 11 | 0.030 |
Why?
|
In Situ Nick-End Labeling | 1 | 2012 | 12 | 0.030 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2012 | 21 | 0.030 |
Why?
|
Microscopy, Fluorescence | 1 | 2012 | 88 | 0.030 |
Why?
|
Mutation | 1 | 2015 | 489 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2012 | 102 | 0.030 |
Why?
|
Matrix Metalloproteinase 7 | 1 | 2012 | 1 | 0.030 |
Why?
|
Frizzled Receptors | 1 | 2012 | 5 | 0.030 |
Why?
|
TCF Transcription Factors | 1 | 2012 | 8 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2017 | 1328 | 0.020 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2009 | 19 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2009 | 36 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 43 | 0.020 |
Why?
|
United States | 1 | 2018 | 3976 | 0.020 |
Why?
|
Rhodanine | 1 | 2009 | 1 | 0.020 |
Why?
|
Thiazolidines | 1 | 2009 | 2 | 0.020 |
Why?
|
Cytochromes c | 1 | 2009 | 3 | 0.020 |
Why?
|
Lipid Peroxides | 1 | 2009 | 8 | 0.020 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2009 | 17 | 0.020 |
Why?
|
Palmitic Acid | 1 | 2009 | 12 | 0.020 |
Why?
|
Adenosine | 1 | 2009 | 59 | 0.020 |
Why?
|
Response Elements | 1 | 2009 | 16 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 153 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2009 | 231 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2009 | 495 | 0.020 |
Why?
|
Dimerization | 1 | 2005 | 23 | 0.020 |
Why?
|
Protein Kinases | 1 | 2005 | 26 | 0.020 |
Why?
|
DNA Primers | 1 | 2005 | 91 | 0.020 |
Why?
|